Definium Therapeutics Inc. Common Shares (DFTX)
Stock · NASDAQ · Health Care
$32.12as of 10/16/2026
Price chart
Active signals
Support level
$22.55
Industry
Medicinal Chemicals and Botanical Products
DFTX Signal Track Record
How signals performed across all stocks →What DFTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | +6.9% | 60% | September 14, 2026 |
| Bollinger Band Breakout | 28 | +7.1% | 57% | June 22, 2026 |
| Bollinger Band BreakdownActive now | 15 | +9.3% | 67% | October 8, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +5.9% | 70% | June 25, 2025 |
| Any 20-session window (baseline) | +1.1% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DFTX
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the…
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- Employees
- 105
- Website
- definiumtx.com/
Fundamentals
- 1-day range
- $33.93$34.79
- Market cap
- $5.03B
- P/E (trailing)
- —
- P/E (forward)
- -17.65
- EPS (trailing)
- $-3.43
- Dividend yield
- —
- Beta
- 2.24
- Avg. volume
- 2.15M
52-week range
$10.47$49.7
Next earnings: November 5, 2026 · EPS estimate $-0.56confirmed
Forecasts
18 analyst ratings
Buy 96%
Hold 4%
Sell 0%
1-year price forecast
High
$91
+183.3%
Median
$71
+121.0%
Low
$55
+71.2%
Definium Therapeutics Inc. Common Shares Competitors
Chosen by industry and closest market cap.
- DFTXDefinium Therapeutics Inc. Common Shares$32.1▼ 6.30%Market cap $5.03BP/E —$10.47$49.7
- RLXRLX Technology Inc. American Depositary Shares each representing the right to receive one (1) Class A ordinary share$1.7▼ 0.58%Market cap $3.08BP/E 14.19$1.65$2.6
- RGCRegencell Bioscience Holdings Limited Ordinary Shares$9.59▲ 0.74%Market cap $2.70BP/E —$4.51$69
- TRLVTrulieve Cannabis Corp. Subordinate Voting Shares$10.01▼ 2.82%Market cap $1.73BP/E —$7.82$12.93
- CRONCronos Group Inc. Common Share$3.21▲ 0.31%Market cap $1.16BP/E 16.88$3.23$4.99
- GLASGlass House Brands Inc. Subordinate Voting Shares$3.19▼ 14.02%Market cap $760.64MP/E —$4.2$14
- TLRYTilray Brands Inc. Common Stock$3.04▼ 5.30%Market cap $517.36MP/E —$3.07$18.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DFTX Definium Therapeutics Inc. Common Shares | $5.03B | — | $32.1 | ▼ 6.30% | $10.47$49.7 |
| RLX RLX Technology Inc. American Depositary Shares each representing the right to receive one (1) Class A ordinary share | $3.08B | 14.19 | $1.7 | ▼ 0.58% | $1.65$2.6 |
| RGC Regencell Bioscience Holdings Limited Ordinary Shares | $2.70B | — | $9.59 | ▲ 0.74% | $4.51$69 |
| TRLV Trulieve Cannabis Corp. Subordinate Voting Shares | $1.73B | — | $10.01 | ▼ 2.82% | $7.82$12.93 |
| CRON Cronos Group Inc. Common Share | $1.16B | 16.88 | $3.21 | ▲ 0.31% | $3.23$4.99 |
| GLAS Glass House Brands Inc. Subordinate Voting Shares | $760.64M | — | $3.19 | ▼ 14.02% | $4.2$14 |
| TLRY Tilray Brands Inc. Common Stock | $517.36M | — | $3.04 | ▼ 5.30% | $3.07$18.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- JP Morgan Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $84benzinga · 10/9/2026
- JP Morgan Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $84Benzinga · 10/9/2026
- Jefferies Highlights Three Biotech Stocks With Blockbuster PotentialYahoo · 9/30/2026
- Definium Therapeutics Announces New Employee Inducement GrantsYahoo · 9/28/2026
- Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and DepressionYahoo · 9/24/2026
- Weekly Roundup on the Cannabis Sector & Psychedelic SectorYahoo · 9/21/2026
- Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is WatchingYahoo · 9/20/2026
- Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety StudyYahoo · 9/19/2026
- Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch NextYahoo · 9/16/2026
Insider Activity
Insider Actions →Acquired
1.43M
Disposed
82.0K
- Daniel Karlin · September 25, 2026 · Sale10.9K @ $36.57
- Robert Barrow · September 25, 2026 · Sale31.6K @ $36.57
- Matthew T. Wiley · September 25, 2026 · Sale3.1K @ $36.57
- Brandi Roberts · September 25, 2026 · Sale3.4K @ $36.57
- Mark Sullivan · September 25, 2026 · Sale14.1K @ $36.57
- Andreas Krebs · September 18, 2026 · Option Exercise1.6K @ $35.52
- Carol A. Vallone · September 18, 2026 · Option Exercise1.1K @ $35.52
- Daniel Karlin · September 14, 2026 · Grant200.0K
- Robert Barrow · September 14, 2026 · Grant750.0K
- Matthew T. Wiley · September 14, 2026 · Grant125.0K
- Brandi Roberts · September 14, 2026 · Grant125.0K
- Mark Sullivan · September 14, 2026 · Grant125.0K
- Robert Barrow · September 3, 2026 · Sale19.0K @ $37.94
- Robert Barrow · September 2, 2026 · Grant40.0K
- Brandi Roberts · August 12, 2026 · Grant62.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 78.08M
- Total value held
- $1.47B
- Institutional holders
- 242
Top holders this quarter
- Unknown8.48M
- Unknown5.91M
- Unknown5.00M
- Unknown3.56M
- Unknown3.00M
- Unknown2.50M
- Unknown2.47M
- Unknown2.44M
- Unknown2.00M
- Unknown1.81M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
JP Morgan Launches Coverage of DFTX with Overweight Rating
JP Morgan has started covering Definium Therapeutics and gave it an overweight rating. The bank set a price target of $84, well above the stock’s 52‑week high of $49.70. This new coverage signals that JPMorgan sees potential upside in the company. The rating and target may affect how investors view the stock.
JP Morgan Launches Coverage of DFTX with Overweight Rating. JP Morgan has started covering Definium Therapeutics and gave it an overweight rating. The bank set a price target of $84, well above the stock’s 52‑week high of $49.70. This new coverage signals that JPMorgan sees potential upside in the company. The rating and target may affect how investors view the stock.